Reportlinker Adds Cancer Analysis

NEW YORK, June 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Analysis

http://www.reportlinker.com/p0550877/Cancer-Analysis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The one-stop online business resource for everyone involved in this high-growth area.

Interest in cancer has never been greater as drug developers pursue a vast range of therapeutic approaches to find effective treatments for one of the world's biggest killers.

Cancer Analysis is a daily-updated online business resource from Espicom. When research time is at a premium, executives need fast access to reliable business information. Having that information in a single daily-updated and easy to search online service brings untold time and efficiency savings.

Cancer Analysis provides:

Company Performance, Products and Research Pipelines

Regularly updated and detailed analysis of over 120 leading companies' strategy, research, products and agreements.

Conference and Meeting Reviews

A distillation of the important news from leading meetings such as ASCO and AACR.

R&D and Product Developments

R&D and product developments in all major cancer areas.

Latest News

Track the research, performance and developments of over 1,700 companies and organisations involved with cancer drugs worldwide.

Companies covered in Cancer Analysis: Access Pharmaceuticals

Active Biotech

ADVENTRX Pharmaceuticals

AEterna Zentaris

Agennix

Alchemia

Allos Therapeutics

Ambrilia Biopharma

Amgen

Agenus

Antisense Pharma

Antisoma

ARIAD Pharmaceuticals

Ark Therapeutics

ArQule

Array BioPharma

AstraZeneca

AVAX Technologies

Bayer

Biogen Idec

BioNumerik Pharmaceuticals

Bristol-Myers Squibb

BTG

Can-Fite BioPharma

CEL-SCI

Celgene

Cell Therapeutics

Cephalon

Clavis Pharma

Cyclacel Pharmaceuticals

Daiichi Sankyo

Dendreon

Eisai

Eli Lilly

Endocyte

EntreMed

Enzon Pharmaceuticals

EpiCept

Exelixis

Gamida Cell

Genmab

Genta

GenVec

Genzyme Oncology

Geron

GlaxoSmithKline

Human Genome Sciences

Idera Pharmaceuticals

ImmunoGen

Immunomedics

Isis Pharmaceuticals

Keryx Biopharmaceuticals

Kyowa Hakko Kirin

Ligand Pharmaceuticals

Lorus Therapeutics

Marshall Edwards

MediGene

Merck KGaA

MethylGene

Micromet

INSYS Therapeutics

Northwest Biotherapeutics

Novartis

OncoGenex Technologies

Oncolytics Biotech

Onyvax

Onyx Pharmaceuticals

OSI Pharmaceuticals

Oxford BioMedica

OXiGENE

Peregrine Pharmaceuticals

Pfizer

Pharmacyclics

PharmaMar

Photocure

Progen Pharmaceuticals

Progenics Pharmaceuticals

Quest PharmaTech

Roche

sanofi-aventis

Seattle Genetics

Spectrum Pharmaceuticals

SuperGen

Synta Pharmaceuticals

Talon Therapeutics

Tamir Biotechnology

Tekmira Pharmaceuticals

Telik

TopoTarget

Transgene

Vical

Vion Pharmaceuticals

Viventia Biotech

Wilex

YM BioSciences

Cancer Analysis is available 24/7 worldwide from any PC with an Internet connection. In addition to rapidly updated independent content, Cancer Analysis customers benefit from the easy-to-use interface, simple but powerful search facility and practical features, such as being able to copy and paste information for use in internal plans, documents and presentations. Cancer Analysis is ideal for single users or as a whole enterprise information solution with a range of flexible distribution packages.

To order this report:

Pathology Industry: Cancer Analysis

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.